Ginkgo Bioworks and the Rwanda Development Board Announce Plans to Develop and Implement New Biosecurity Capabilities in Rwanda

Ginkgo Bioworks and the Rwanda Development Board Announce Plans to Develop and Implement New Biosecurity Capabilities in Rwanda

Collaboration aims to leverage innovative biosecurity capabilities to promote global health security and accelerate the development of the regional bioeconomy

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and the Rwanda Development Board ("RDB"), representing the government of the Republic of Rwanda today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent of developing and implementing new biosecurity capabilities in Rwanda .

(PRNewsfoto/Ginkgo Bioworks)

The initial goal of the planned partnership is to support Rwanda's public health institutions as they work to address biosecurity challenges in the region. Ginkgo, through its biosecurity and public health initiative, Concentric by Ginkgo ("Concentric"), plans to collaborate on the ground with RDB to equip these institutions with biosecurity tools and training as well as the secure data infrastructure they need to leverage automation, data analysis, bioinformatics capabilities, and other critical genomic sequencing technologies.

Concentric leverages a nationwide laboratory network to provide pathogen monitoring capabilities across thousands of sites in the U.S., including schools, airports, and other congregate settings. Concentric aims to build sustainable global biosecurity infrastructure to prepare for the next new variant or novel pathogen, and this planned partnership with RDB is a significant milestone in its international expansion as it continues to scale its biosecurity offering.

RDB, a Rwandan government institution, was established in 2008 to accelerate Rwanda's economic development by enabling private sector growth. Ginkgo will build relationships with Rwandan public health institutions and private sector-led biotechnology initiatives in Rwanda ; the RDB will contribute expertise in skills development and on-the-ground support for the partnership.

Concentric and RDB recognize the importance of international collaboration and cooperation to promote global health security as biological threats emerge. Effective pathogen monitoring and data sharing capabilities can empower government officials, community leaders, and other stakeholders to make informed public health decisions. In the long-term, these capabilities can also be leveraged to form the foundation for a sustainable regional bioeconomy. For example, in the context of this MOU, Ginkgo and RDB plan to collaborate to inform workforce development priorities in the areas of biotechnology, biomanufacturing, and bioengineering, and to explore potential opportunities for Rwanda to leverage its biodiversity as a foundation for innovation within its bioeconomy.

"The future of biosecurity is global—COVID-19 has shown us all that pathogens don't recognize national borders. To prepare for the next biological threat, we need the infrastructure in place to build a global weather map tracking the spread and evolution of infectious diseases," said Matt McKnight , General Manager, Biosecurity at Ginkgo Bioworks. "We deeply appreciate Rwanda's leadership working to define a new era of biosecurity, and we are incredibly excited to use our platform to support Rwanda's public health institutions with critical capabilities that we believe will help them face challenges ranging from this pandemic to agricultural and travel biosecurity."

Clare Akamanzi, Chief Executive Officer of the Rwanda Development Board, noted, "The COVID-19 pandemic has exposed the need for robust public health and biotechnology infrastructure in Rwanda and around the world. We are excited about our plans to partner with Ginkgo to bring cutting-edge biosecurity capabilities to Rwanda across various sectors including health and agriculture. We believe this will stimulate our growing bioeconomy and help us learn more about our biodiversity."

About Ginkgo Bioworks

Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visit www.ginkgobioworks.com .

About the Rwanda Development Board

The Rwanda Development Board is a government agency responsible for leading the country's transformation into a dynamic global hub for business, investment, tourism and innovation. Its mission is to fast-track economic development in Rwanda by enabling private sector growth. For more information visit www.rdb.rw .

Forward-Looking Statements of Ginkgo Bioworks

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential success of the partnership and Ginkgo's biosecurity platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the effect of Ginkgo's business combination with Soaring Eagle Acquisition Corp. ("Soaring Eagle") on Ginkgo's business relationships, performance, and business generally, (ii) risks that the business combination disrupts current plans of Ginkgo and potential difficulties in Ginkgo's employee retention, (iii) the outcome of any legal proceedings that may be instituted against Ginkgo related to its business combination with Soaring Eagle, (iv) volatility in the price of Ginkgo's securities now that it is a public company due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, changes in laws and regulations affecting Ginkgo's business and changes in the combined capital structure, (v) the ability to implement business plans, forecasts, and other expectations after the completion of the business combination, and identify and realize additional opportunities, (vi) the risk of downturns in demand for products using synthetic biology, (vii) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID-19 testing and the commercial viability of our COVID-19 testing business, (viii) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, and (ix) our ability to close and realize the expected benefits of pending merger and acquisition transactions. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC") on May 16, 2022 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

GINKGO MEDIA CONTACT:
press@ginkgobioworks.com

GINKGO INVESTOR CONTACT:
investors@ginkgobioworks.com

RDB MEDIA CONTACT:
Doreen Ingabire
Head of Communications
communications@rdb.rw

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/ginkgo-bioworks-and-the-rwanda-development-board-announce-plans-to-develop-and-implement-new-biosecurity-capabilities-in-rwanda-301603914.html

SOURCE Ginkgo Bioworks

News Provided by PR Newswire via QuoteMedia

DNA
The Conversation (0)
QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period

QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a decision to discontinue the NeuMoDx 96 and 288 Molecular Systems in light of the market development trends for these product lines following the COVID-19 pandemic and changing customer needs for integrated PCR-based clinical molecular testing systems.

This decision will allow QIAGEN to refocus resources and efforts on developing and commercializing other innovative solutions within its portfolio, in particular the QIAstat-Dx system for syndromic testing, the QIAcuity portfolio of digital PCR systems and the QIAGEN Digital Insights (QDI) bioinformatics business. These are complemented by QIAGEN building on proven leadership positions in Sample technologies and the QuantiFERON-TB franchise.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe

QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy number variation (CNV) analysis for use on its digital PCR platform QIAcuity and several other enhancements in its GeneGlobe Design and Analysis Hub, a comprehensive research platform that integrates pre-designed assays with a database of more than 10,000 biological entities including genes, miRNAs, and pathways. The new advancements aim to support customers with a wide range of assay customization options, from simple to complex and validated multiplex assays, while further improving the user experience.

Genetic research is moving fast, and new target genes are rapidly evolving that are not covered by standard or pre-designed assays. To keep pace and close the need gap, the new digital PCR Custom Assay Design Tool has been developed as an interface on the GeneGlobe platform. It enables customers to design and order assays for use on QIAGEN's digital PCR platform QIAcuity outside of QIAGEN's comprehensive catalog of over 200 wet-lab validated assays for copy number variations profiling in translational cancer research. Copy number variations (CNVs) are a type of genetic variation where specific segments of the DNA are copied more or fewer times than normal in the genome, potentially affecting susceptibility to diseases and response to treatment.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from six poster presentations at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy.

The clinical poster presentations highlight the continued potent antiviral activity of ALG-000184 for chronic hepatitis B (CHB) in both HBeAg-positive and HBeAg-negative subjects.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost

Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that it has completed integration of its latest chemistry, XLEAP-SBS ™ into all reagents for its NextSeq ™ 1000 and NextSeq 2000 next-generation sequencing (NGS) instruments.

"We are excited to deliver for our NextSeq 1000/2000 customers improved sequencing with faster run times, better quality, and higher output—all at lower cost per kit," said Jason Johnson , head of Global Product Management at Illumina. "XLEAP-SBS chemistry on NextSeq 1000/2000 will enable labs to perform bigger NGS projects without raising the budget, and facilitate greater adoption of multiomic approaches."

In March, the company launched its P4 flow cell (highest output of 540 Gb) with XLEAP-SBS chemistry for the NextSeq 2000, and today it announced that the XLEAP-SBS P1, P2, and P3 flow cells are all now available. XLEAP-SBS chemistry is a faster, higher quality, and more robust sequencing-by-synthesis chemistry that delivers approximately 20% faster turnaround times.

Early-access customers have shared positive feedback on improved quality, stability, and run times. Marc Monot , PhD, head of Biomics at the Institut Pasteur, said, "We were very happy with the quantity and quality of the reads. The Q is very close to Q40 and the stability is a game changer for Illumina. From the first base to the last base, [Illumina] improved the quality of the run quite a lot."

The NextSeq 1000 and NextSeq 2000 Systems are flexible and scalable mid-throughout sequencers that enable a range of applications, including single-cell, whole-exome, and RNA sequencing.

Use of forward-looking statements

This release contains forward-looking statements that involve risks and uncertainties, including the expectation for lower costs related to the storing and managing of genomic data costs. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including meeting manufacturing, quality, and performance requirements; (ii) our ability to deploy new products, services, and applications, and to expand the markets for our technology platforms; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations once deployed, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X , Facebook , LinkedIn , Instagram , TikTok , and YouTube

Contacts

Investors:  
Salli Schwartz
858-291-6421
IR@illumina.com

Media:  
Samantha Beal
PR@illumina.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/illumina-launches-latest-chemistry-across-most-popular-mid-throughput-sequencers-enabling-higher-quality-and-greater-speed-for-customers-at-lower-cost-302162971.html

SOURCE Illumina, Inc.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET®  as First and Only Treatment for People with Acute Hepatitis C Virus

U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® as First and Only Treatment for People with Acute Hepatitis C Virus

  • MAVYRET ® (glecaprevir/pibrentasvir) is the first and only oral eight-week pangenotypic treatment option approved for people with acute or chronic hepatitis C virus (HCV)*
  • With this approval, providers can now treat HCV patients immediately at the time of diagnosis
  • HCV is a curable condition, but patients can often go undiagnosed. 1 If left untreated, people with acute HCV   could progress to chronic disease, including liver-related complications, such as cirrhosis or liver cancer 1
  • The approval supports global clinical guidelines to advance testing and treatment for people with HCV regardless of chronicity, and supports public health goals for disease elimination

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET ® (glecaprevirpibrentasvir), an oral pangenotypic direct acting antiviral (DAA) therapy. It is now approved for the treatment of adults and pediatric patients three years and older with acute or chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. With this approval, MAVYRET is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a 96% cure rate. 2,†

HCV is a highly infectious blood-borne disease affecting the liver. 1 People recently infected, or those with acute HCV, may not have symptoms. 1 If left untreated, HCV could lead to liver-related complications, such as cirrhosis or liver cancer. 1 The United States is expected to incur ~$120 billion in total medical costs over the next 10 years through 2035 linked to chronic liver disease and other related conditions caused by untreated HCV. 3

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award Contest to Support Their Professional Goals

AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award Contest to Support Their Professional Goals

  • The AbbVie Migraine Career Catalyst Award™ contest is now open for entries, offering financial support to help winners pursue career and professional development goals.
  • As the only company with three approved products designed to meet patient needs across the spectrum of migraine, AbbVie is   committed to supporting the migraine community beyond treatment.
  • Migraine affects productivity and career growth—up to 90% of people with migraine report it interferes with their ability to function at work, highlighting the need for meaningful support beyond treatment.

- AbbVie (NYSE: ABBV) today announced the second annual AbbVie Migraine Career Catalyst Award ™ contest is now accepting entries. AbbVie is proud to continue this nationwide initiative supporting people living with migraine by awarding 20 entrants with $2,500 each that they may use to pursue their personal, professional, and educational goals.

"Migraine can be an invisible barrier to success in the workplace where the condition is often misunderstood or stigmatized," said Carl Cincinnato , executive director, Migraine at Work, a nonprofit initiative under the World Health Education Foundation dedicated to improving workplace environments for individuals living with migraine. "Initiatives like the AbbVie Migraine Career Catalyst Award™ contest not only provide financial support but also serve as a powerful form of advocacy for people living with migraine."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 . Management will participate in a fireside chat at 10:20 a.m. Central time .

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be available later that day.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
AbbVie Partners with Chicago Cubs on "Striking Out Cancer"

AbbVie Partners with Chicago Cubs on "Striking Out Cancer"

Chicago -based institutions aim to create greater awareness for cancer advocacy and to support non-profit cancer organizations

AbbVie (NYSE: ABBV) announced a multi-year partnership with the Chicago Cubs to support people living with cancer through a campaign called "Striking Out Cancer" which starts today when the Chicago Cubs play the Cincinnati Reds. As part of the first year of the partnership, AbbVie will make a $233 donation for every strikeout by a Chicago Cubs pitcher at home during the 2025 regular season. The donation amount is in honor of the approximately 233 Americans diagnosed with cancer every hour, according to the American Cancer Society. 1

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×